Verve Therapeutics recently announced the first human dosing with VERVE-101, an investigational base-editing therapy that is designed to treat...

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

Verve Therapeutics announced last week that its clinical trial application for VERVE-101 in heterozygous familial hypercholesterolemia had been...

In 2022, we celebrate a decade of CRISPR as a game-changing tool in research and medicine. The last 10 years have been phenomenal, and CRISPR cures...

A recent study reports the first ever application of base editing to protect immune cells against HIV infection. This is achieved without introducing...

2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...